Microbot Medical's New Patent Opens Doors in Robotics Field
Microbot Medical Secures New Patent for Enhanced Robotics
Microbot Medical Inc., a pioneering company in medical robotics, has recently made headlines with a new patent granted by the United States Patent and Trademark Office (USPTO). This patent covers a modular robotic surgical system, where a base is complemented by multiple tool-receiver units that can be attached independently. This innovative approach positions the LIBERTY® Endovascular Robotic System for broader applications in endovascular procedures.
Implications for Market Expansion
The significance of this patent cannot be overstated. It is expected to substantially broaden the Total Addressable Market (TAM) for the LIBERTY® system, estimating the potential for future adaptations in various endovascular procedures. Currently, the company holds a robust portfolio consisting of 12 granted patents globally and 57 pending applications.
Innovation and Customization
This new patent actively promotes customization tailored for varying clinical needs. Microbot Medical aims to leverage this flexibility to enhance its system capabilities and potentially address numerous clinical indications. The implications are substantial, as the anticipated market could expand well beyond the 2.5 million peripheral endovascular procedures currently performed annually in the United States alone.
Leadership Insights
Harel Gadot, Chairman and CEO of Microbot Medical, expressed enthusiasm regarding the patent's potential impact, emphasizing that LIBERTY® stands out as a highly distinctive system within the medical robotics ecosystem. It is recognized for being the first fully disposable robotic system, combined with its modular features. Gadot stated that this patent furthers their differentiation in the marketplace, potentially allowing for adaptability across more than six million annual endovascular procedures in the U.S.
Current Status of LIBERTY® System
It’s essential to note that the LIBERTY® system is still under investigational status, waiting for the FDA's 510(k) clearance which means it is not commercially available in the U.S. at this time. However, the anticipation surrounding the system suggests promising futures for Microbot Medical and their operations.
About Microbot Medical Inc.
Microbot Medical Inc. (NASDAQ: MBOT) is positioned at the forefront of medical technology innovation. The company's vision revolves around revolutionizing endovascular robotics to enhance treatment accessibility for patients worldwide. The development of a fully disposable endovascular robotic system marks a significant advancement, aiming to dismantle traditional barriers previously faced by healthcare providers utilizing robotic systems.
Future Outlook and Developments
Looking forward, the company’s strategic intentions focus on increasing its commercial readiness while navigating through the regulatory landscape. As they await the FDA’s decision, Microbot Medical is poised for significant developments whilst remaining focused on enhancing their offerings within the peripheral market. With the issuance of this latest patent, it seems the company is gearing up for an exciting chapter in their journey, potentially transforming the application of endovascular robotic systems.
Frequently Asked Questions
What recent achievement did Microbot Medical announce?
Microbot Medical secured a new patent for its LIBERTY® Endovascular Robotic System, expanding its market capabilities.
How many patents does Microbot Medical currently hold?
Microbot Medical has 12 granted patents globally and 57 pending patent applications.
What is the potential market for the LIBERTY® system?
The LIBERTY® system could address over 6 million endovascular procedures annually in the U.S., significantly expanding its market presence.
Is the LIBERTY® system currently available for sale?
No, the LIBERTY® system is under investigation and pending FDA 510(k) clearance, thus not available for sale in the U.S.
What is the vision of Microbot Medical?
Microbot Medical's vision is to redefine endovascular robotics and improve care quality for healthcare providers and patients worldwide.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.